Home Tags FORWARD I trial

Tag: FORWARD I trial

ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine

Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...

Data Highlights the Potential to Combine Mirvetuximab Soravtansine with an Immune...

Preclinical data demonstrate the potential for enhancing the activity of mirvetuximab soravtansine, also known as IMGN853, when the investigational agent is combined with and...

Treatment Response to Mirvetuximab Soravtansine Found to be Substantially Greater in...

Findings with mirvetuximab soravtansine (also known as IMGN853 and M9346A-sulfo-SPDB-DM4), a novel folate receptor alpha (FRα)-targeting antibody-drug conjugate being developed by ImmunoGen, a clinical-stage...